- Record: found
- Abstract: not found
- Article: not found
Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial
Antoni Torres ,
Nanshan Zhong ,
Jan Pachl ,
Jean-François Timsit ,
Marin Kollef ,
Zhangjing Chen ,
Jie Song ,
Dianna Taylor ,
Peter J Laud ,
Gregory G Stone ,
Joseph W Chow
December 2017
December 2017
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Nosocomial pneumonia is commonly associated with antimicrobial-resistant Gram-negative
pathogens. We aimed to assess the efficacy and safety of ceftazidime-avibactam in
patients with nosocomial pneumonia, including ventilator-associated pneumonia, compared
with meropenem in a multinational, phase 3, double-blind, non-inferiority trial (REPROVE).